Advanced cutaneous squamous cell carcinoma (CSCC) | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

The hallmark of cSCC is the malignant transformation of healthy epidermal keratinocytes. Advanced cutaneous squamous cell carcinoma typically develops early. TP53, a well-researched tumor suppressor gene, functional loss is one important pathogenic event that leads to the emergence of apoptotic resistance. When squamous skin cancer has spread, is aggressive or resistant to several treatments, and recurs, it is regarded as advanced. It can be treated with surgery, radiation therapy, topical therapy, or photodynamic therapy. One of the most prevalent cancers in the US is cutaneous squamous cell carcinoma (cSCC), and in recent years, its incidence has increased. The incidence of cSCC continues to rise globally despite growing public awareness of the causes of skin cancer and the value of avoiding prolonged sun exposure. Electrical curettage is a treatment option for low-risk cutaneous squamous cell carcinoma (cSCC) of the trunk and extremities. The two main forms of treatment for aggressive cSCC, surgical resection and Moss microsurgery, have comparable cure rates with careful patient selection. Radiation therapy can be used as the first line of treatment for patients who are unable to undergo surgery, but it is frequently used as an adjunct to surgery to better control the area.

Description

The hallmark of cSCC is the malignant transformation of healthy epidermal keratinocytes. Advanced cutaneous squamous cell carcinoma typically develops early. TP53, a well-researched tumor suppressor gene, functional loss is one important pathogenic event that leads to the emergence of apoptotic resistance. When squamous skin cancer has spread, is aggressive or resistant to several treatments, and recurs, it is regarded as advanced. It can be treated with surgery, radiation therapy, topical therapy, or photodynamic therapy. Although CSCC is not usually fatal, it can cause serious morbidity, especially when the skin of the face is involved. Most cSCCs are in the head and neck region and can lead to extensive excision, which is necessary in advanced stages of the disease. In addition, the cost of treatment has been shown to be a significant burden on public health. Nonmelanoma skin cancer was the fifth most expensive type of head and neck cancer treatment in an American Medical Association study. Diagnosis of CSCC begins with a thorough history and physical examination. All lesions suspected to be skin tumors should be biopsied to rule out basal cell carcinoma and other skin lesions. Given the vital role of ultraviolet radiation (UVR) in the pathogenesis of cSCC, approaches aimed at reducing UV exposure are a cornerstone of cSCC prevention. In addition, local treatment of precancerous lesions and SCC may prevent the development of invasive lesions in the future.

Advanced cutaneous squamous cell carcinoma (CSCC) (Epidemiology)

The incidence of cSCC continues to rise globally despite growing public awareness of the causes of skin cancer and the value of avoiding prolonged sun exposure. According to a study that examined skin cancer cases in South Korea between 1999 and 2014, the incidence of the disease increased steadily over time, with average annual percentage changes for men and women of 3.3 and 6.8, respectively. The second most prevalent type of skin cancer and one of the most prevalent in the US is cutaneous squamous cell carcinoma (cSCC). In the United States, 3.5 million cases of nonmelanoma skin cancer were identified in 2006: of these, approx. 20% basal cell carcinoma and 80% basal cell carcinoma. Additionally, a growing number of patients are receiving immunosuppressive medication and solid organ transplants for a variety of rheumatic and dermatological diseases. As previously mentioned, solid organ transplant recipients are much more likely to develop SCC. In this group, metastatic disease may also be more prevalent. Patients who resided close to the equator tended to be younger than those who lived so farther away. With 1.17 non-melanoma skin cancer cases per 100 people, five times more than all other cancers combined, Australia has the highest incidence of cSCC. The region's high concentration of Caucasians and sun exposure may be to blame for the high incidence. Men are 2-3 times more likely than women to develop SCC, which may be linked to the increased lifetime UV exposure that men experience. This higher exposure could be attributed to the higher participation of men in professions that expose them to more sunlight or other occupational hazards like soot, oil, or tar. Around 70 is the typical age to apply for SCC. It varies considerably, though, and in some high-risk groups (e.g., SCC frequently manifests at a younger age), including in transplant recipients, epidermolysis bullosa patients, and epidermolysis bullosa patients.

Advanced cutaneous squamous cell carcinoma (CSCC) -Current Market Size & Forecast Trends

The market for advanced cutaneous squamous cell carcinoma (CSCC) is expected to experience significant growth, with estimates indicating a value of approximately USD 10.31 billion in 2020 and projected to grow at a compound annual growth rate (CAGR) of 7.2% during the forecast period. Overall, the advanced CSCC market is well-positioned for substantial growth through 2035 as new therapies and improved treatment modalities continue to emerge.

Electrical curettage is a treatment option for cutaneous squamous cell carcinoma (cSCC) of low risk that affects the trunk and extremities. The two main therapies for aggressive cSCC are surgical resection and Moss microsurgery; with careful patient selection, these treatments have comparable cure rates. Radiation therapy can be used as the first line of treatment for patients who are unable to undergo surgery, but it is frequently used as an adjunct to surgery to better control the area. Chemotherapy may be thought of as adjuvant therapy in certain high-risk cSCC cases. Epidermal growth factor receptor (EGFR) inhibitors may be used in conjunction with surgery, according to newly available evidence. Systemic chemotherapy may be a possibility for people with metastatic cSCC. In terms of managing cSCC, prevention is crucial. Approaches aimed at reducing UV exposure are a cornerstone of cSCC prevention because ultraviolet radiation (UVR) plays a crucial role in the pathogenesis of the disease. Actinic keratosis and localized carcinomas are two effective therapies for precancerous skin lesions. The majority of these procedures can be done easily as outpatients. Complete surgical resection is necessary for patients with localized cSCC. Inoperable tumors and patients who are not scheduled for surgery should receive radiotherapy. Systemic therapy is recommended for cSCC that has spread locally or has metastasized locally or distantly and cannot be treated with surgery or radiotherapy. No specific suggestions for systemic therapy in patients with locally advanced disease or metastatic cSCC can be made due to the lack of prospective randomized phase 3 studies evaluating and comparing the efficacy and safety of chemotherapy, epidermal growth factor receptor (EGFR) inhibitors, and anti-PD-1 antibodies. With response rates of up to 50% in locally advanced and metastatic cSCC, anti-PD-1 antibodies are currently showing encouraging results. In comparison to EGFR inhibitors, anti-PD-1 antibodies appear to be more effective and appear to prolong responses longer than chemotherapy and EGFR inhibitors. When compared to chemotherapy, the side effects of anti-PD-1 antibodies seem to be more favorable. The use of PD-1 inhibitors as a new standard of care for patients with locally advanced and metastatic cSCC is promising, in conclusion. In patients undergoing high-risk cSCC resection and radiation therapy, the adjuvant use of cemiplimab and pembrolizumab is currently being studied in placebo-controlled clinical trials. For patients who are not candidates for anti-PD-1 therapy, transplant recipients or patients who are resistant to EGFR inhibitors, anti-PD-1 antagonists, and/or chemotherapy may be suggested. Chemotherapy has a higher response rate than EGFR inhibitors, despite the latter's better toxicity profile. As a result, EGFR inhibitors are better suited for elderly patients who are ill or who are frail. Combining EGFR inhibitors with regional therapies like surgery or radiation therapy can increase the response rate and response time.

Report Highlights

Advanced cutaneous squamous cell carcinoma (CSCC) - Current Market Trends

Advanced cutaneous squamous cell carcinoma (CSCC) - Current & Forecasted Cases across the G8 Countries

Advanced cutaneous squamous cell carcinoma (CSCC) - Market Opportunities and Sales Potential for Agents

Advanced cutaneous squamous cell carcinoma (CSCC) - Patient-based Market Forecast to 2035

Advanced cutaneous squamous cell carcinoma (CSCC) - Untapped Business Opportunities

Advanced cutaneous squamous cell carcinoma (CSCC) - Product Positioning Vis-a-vis Competitors' Products

Advanced cutaneous squamous cell carcinoma (CSCC) - KOLs Insight